Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

INDPIndaptus Therapeutics, IncRunning, no new patients

Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors

Solid Tumor, Adult · HCC - Hepatocellular Carcinoma · CRC (Colorectal Cancer) · Pancreatic Adenocarcinoma · NSCLC Non-small Cell Lung Cancer · Squamous Cell Cancer of the Head and Neck · UC (Urothelial Cancer) · MSI-H Cancer

0Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

No warning signs right now. That's why the score is 0.

Score over time

Stage
Phase 1/2
Patients
120 (planned)
Started
Feb 28, 2023
Main results expected
Jun 30, 2027
Fully finished
Sep 30, 2027
Results posted
not yet

What counts as success

The trial's main goal(s), called the “primary outcome.”

  • Number of Subjects with dose-limiting toxicities (DLTs)

    Measured over: Through study completion, up to 3 years

  • Percentage of subjects with Adverse Events (AEs)

    Measured over: Through completion, up to 3 years

  • Maximum Tolerated Dose (MTD) of Decoy20

    Measured over: Up to 2 years

  • Recommended Phase 2 Dose (RP2D) of Decoy20

    Measured over: Up to 2.5 years

Changes Tremor has spotted

No changes since Tremor started watching this trial.
Show details (technical version)

Score inputs

  • none

Raw record changes

  • none yet

Trial ID NCT05651022 · record last updated 2026-01-13 · checked 2026-11-09 15:47 UTC

See the official record on ClinicalTrials.gov (NCT05651022) ↗